Chinese General Practice ›› 2022, Vol. 25 ›› Issue (26): 3298-3307.DOI: 10.12114/j.issn.1007-9572.2022.0301
Special Issue: 泌尿系统疾病最新文章合集
• Original Research • Previous Articles Next Articles
Received:
2022-02-28
Revised:
2022-06-10
Published:
2022-09-15
Online:
2022-07-06
Contact:
Xiangmei CHEN
About author:
通讯作者:
陈香美
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0301
组别 | 只数 | 体征量化分值 |
---|---|---|
正常对照组 | 6 | -4.73±1.69a |
MRL/lpr组 | 3 | 5.37±2.04 |
SY低剂量组 | 5 | 1.46±1.51 |
SY中剂量组 | 7 | -2.13±2.23a |
SY高剂量组 | 9 | -0.15±2.49a |
F值 | 13.96 | |
P值 | <0.001 |
Table 1 Comparison of quantitative scores of signs of mice in five groups
组别 | 只数 | 体征量化分值 |
---|---|---|
正常对照组 | 6 | -4.73±1.69a |
MRL/lpr组 | 3 | 5.37±2.04 |
SY低剂量组 | 5 | 1.46±1.51 |
SY中剂量组 | 7 | -2.13±2.23a |
SY高剂量组 | 9 | -0.15±2.49a |
F值 | 13.96 | |
P值 | <0.001 |
组别 | 只数 | 干预第9周 | 干预第10周 | 干预第11周 | 干预第12周 | 干预第13周 |
---|---|---|---|---|---|---|
正常对照组 | 6 | 0.20±0.11a | 0.40±0.02a | 0.28±0.03a | 0.19±0.07a | 0.39±0.05a |
MRL/lpr组 | 3 | 0.69±0.26 | 0.88±0.33 | 0.84±0.30 | 0.90±0.12 | 0.90±0.17 |
SY低剂量组 | 5 | 0.32±0.02a | 0.46±0.06a | 0.36±0.07a | 0.27±0.10a | 0.45±0.10a |
SY中剂量组 | 7 | 0.27±0.03a | 0.43±0.14a | 0.36±0.04a | 0.45±0.25a | 0.43±0.05a |
SY高剂量组 | 9 | 0.25±0.07a | 0.52±0.24a | 0.33±0.05a | 0.34±0.14a | 0.46±0.09a |
F值 | 13.58 | 3.13 | 12.80 | 14.54 | 20.97 | |
P值 | <0.001 | 0.047 | <0.001 | <0.001 | <0.001 |
Table 2 Comparison of UPCR among 5 groups at 9,10,11,12 and 13 weeks after intervention
组别 | 只数 | 干预第9周 | 干预第10周 | 干预第11周 | 干预第12周 | 干预第13周 |
---|---|---|---|---|---|---|
正常对照组 | 6 | 0.20±0.11a | 0.40±0.02a | 0.28±0.03a | 0.19±0.07a | 0.39±0.05a |
MRL/lpr组 | 3 | 0.69±0.26 | 0.88±0.33 | 0.84±0.30 | 0.90±0.12 | 0.90±0.17 |
SY低剂量组 | 5 | 0.32±0.02a | 0.46±0.06a | 0.36±0.07a | 0.27±0.10a | 0.45±0.10a |
SY中剂量组 | 7 | 0.27±0.03a | 0.43±0.14a | 0.36±0.04a | 0.45±0.25a | 0.43±0.05a |
SY高剂量组 | 9 | 0.25±0.07a | 0.52±0.24a | 0.33±0.05a | 0.34±0.14a | 0.46±0.09a |
F值 | 13.58 | 3.13 | 12.80 | 14.54 | 20.97 | |
P值 | <0.001 | 0.047 | <0.001 | <0.001 | <0.001 |
组别 | 只数 | anti-dsDNA | ANA |
---|---|---|---|
正常对照组 | 6 | 0.76±0.21a | 0.24±0.02a |
MRL/lpr组 | 3 | 1.53±0.04 | 0.50±0.06 |
SY低剂量组 | 5 | 1.18±0.06a | 0.34±0.04a |
SY中剂量组 | 7 | 1.59±0.05 | 0.33±0.04a |
SY高剂量组 | 9 | 1.19±0.16a | 0.34±0.02a |
F值 | 25.06 | 23.79 | |
P值 | <0.001 | <0.001 |
Table 3 Comparison of serum anti-dsDNA and ANA levels in five groups of mice after 14 weeks of intervention
组别 | 只数 | anti-dsDNA | ANA |
---|---|---|---|
正常对照组 | 6 | 0.76±0.21a | 0.24±0.02a |
MRL/lpr组 | 3 | 1.53±0.04 | 0.50±0.06 |
SY低剂量组 | 5 | 1.18±0.06a | 0.34±0.04a |
SY中剂量组 | 7 | 1.59±0.05 | 0.33±0.04a |
SY高剂量组 | 9 | 1.19±0.16a | 0.34±0.02a |
F值 | 25.06 | 23.79 | |
P值 | <0.001 | <0.001 |
组别 | 只数 | C3( | IgG〔M(P25,P75)〕 | C5b-9( |
---|---|---|---|---|
正常对照组 | 6 | 3.65±3.14a | 4.57(3.14,20.06) | 0.00±0.00a |
MRL/lpr组 | 3 | 142.70±87.02 | 69.14(38.18,98.68) | 0.34±0.13 |
SY低剂量组 | 5 | 0.41±0.48a | 1.22(0.82,1.51)a | 0.04±0.01a |
SY中剂量组 | 7 | 0.36±0.47a | 2.61(1.78,3.81) | 0.13±0.03a |
SY高剂量组 | 9 | 0.14±0.04a | 1.10(0.92,1.21)a | 0.17±0.03a |
F(H)值 | 7.93 | 16.73b | 13.57 | |
P值 | 0.004 | 0.002 | <0.001 |
Table 4 Comparison of immune deposition of C3,IgG and C5b-9 in kidney tissue of 5 groups of mice after 14 weeks of intervention
组别 | 只数 | C3( | IgG〔M(P25,P75)〕 | C5b-9( |
---|---|---|---|---|
正常对照组 | 6 | 3.65±3.14a | 4.57(3.14,20.06) | 0.00±0.00a |
MRL/lpr组 | 3 | 142.70±87.02 | 69.14(38.18,98.68) | 0.34±0.13 |
SY低剂量组 | 5 | 0.41±0.48a | 1.22(0.82,1.51)a | 0.04±0.01a |
SY中剂量组 | 7 | 0.36±0.47a | 2.61(1.78,3.81) | 0.13±0.03a |
SY高剂量组 | 9 | 0.14±0.04a | 1.10(0.92,1.21)a | 0.17±0.03a |
F(H)值 | 7.93 | 16.73b | 13.57 | |
P值 | 0.004 | 0.002 | <0.001 |
组别 | 只数 | α-SMA | CollagenⅠ | Fibronectin | C3 | C5 | CD35 |
---|---|---|---|---|---|---|---|
正常对照组 | 6 | 0.66±0.32 | 0.59±0.08 | 0.19±0.04a | 0.69±0.30 | 0.82±0.34 | 0.37±0.05a |
MRL/lpr组 | 3 | 1.23±0.71 | 0.96±0.13 | 0.83±0.02 | 0.92±0.19 | 0.84±0.17 | 0.92±0.07 |
SY低剂量组 | 5 | 0.66±0.20 | 0.81±0.25 | 0.45±0.02a | 0.28±0.14a | 0.34±0.11a | 0.31±0.01a |
SY中剂量组 | 7 | 0.54±0.50 | 0.67±0.23 | 0.24±0.01a | 0.34±0.16a | 0.19±0.13a | 0.65±0.02a |
SY高剂量组 | 9 | 0.22±0.16a | 0.20±0.03a | 0.27±0.03a | 0.19±0.08a | 0.18±0.12a | 0.20±0.02a |
F值 | 2.19 | 8.80 | 281.60 | 7.99 | 8.86 | 156.50 | |
P值 | 0.144 | 0.003 | <0.001 | 0.004 | 0.003 | <0.001 |
Table 5 Comparison of the levels of α-SMA,CollagenⅠ,fibronectin and complement protein in kidney tissue of 5 groups of mice after 14 weeks of intervention
组别 | 只数 | α-SMA | CollagenⅠ | Fibronectin | C3 | C5 | CD35 |
---|---|---|---|---|---|---|---|
正常对照组 | 6 | 0.66±0.32 | 0.59±0.08 | 0.19±0.04a | 0.69±0.30 | 0.82±0.34 | 0.37±0.05a |
MRL/lpr组 | 3 | 1.23±0.71 | 0.96±0.13 | 0.83±0.02 | 0.92±0.19 | 0.84±0.17 | 0.92±0.07 |
SY低剂量组 | 5 | 0.66±0.20 | 0.81±0.25 | 0.45±0.02a | 0.28±0.14a | 0.34±0.11a | 0.31±0.01a |
SY中剂量组 | 7 | 0.54±0.50 | 0.67±0.23 | 0.24±0.01a | 0.34±0.16a | 0.19±0.13a | 0.65±0.02a |
SY高剂量组 | 9 | 0.22±0.16a | 0.20±0.03a | 0.27±0.03a | 0.19±0.08a | 0.18±0.12a | 0.20±0.02a |
F值 | 2.19 | 8.80 | 281.60 | 7.99 | 8.86 | 156.50 | |
P值 | 0.144 | 0.003 | <0.001 | 0.004 | 0.003 | <0.001 |
Figure 6 Electropherogram of the effect of Fufangshenyi Decoction on α-SMA,CollagenⅠ,fibronectin and complement proteins in the kidney tissue of the mouse model of lupus nephritis
Figure 7 Pathway map of the effect of Fufangshenyi Decoction on the regulation of complement proteins in the kidney tissue of the mouse model of lupus nephritis
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
赵淑珍,陈香美,于家菊,等. 莲慈汤对7/8肾切除大鼠转化生长因子β表达及肾小球硬化的影响[J]. 中国中西医结合杂志,1997(S1):96-97,286.
|
[9] |
李非,白雪源,陈香美,等. 利用基因芯片探讨中药复方对MRL/lpr狼疮小鼠肾脏基因表达及Th1/Th2细胞的调节作用[J]. 中国中西医结合杂志,2003,23(3):198-200,206. DOI:10.3321/j.issn:1003-5370.2003.03.011.
|
[10] |
李非,陈香美,傅博,等. 肾怡对狼疮小鼠免疫器官内Th1/Th2细胞比例的调节作用[J]. 中国免疫学杂志,2003,19(6):393-396.
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] | |
[16] | |
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||